Verseon bets physics can take drug design beyond AI's training data

Verseon, a computational drug design firm founded in 2002, claims its physics-based platform can discover novel small-molecule drugs outside the chemical space explored by AI training data, including reversible anticoagulants with lower bleeding risk than current therapies like Eliquis and Xarelto.

This Wire brief tracks EternaFusion, and It sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.